86-OR: Primary Results from Two Phase 3 Trials of Faricimab for Diabetic Macular Edema (DME): YOSEMITE and RHINE
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-86-or
Abstract: The leading cause of vision loss in people with diabetic retinopathy (DR) is DME. Intravitreal anti-VEGF therapy is the standard of care for DME; however, optimal vision outcomes are difficult to achieve, and the need… read more here.
Keywords: employee; self genentech; roche pharma; dme ... See more keywords